Half Year 2026 Healius Ltd Earnings Call Transcript
Key Points
- Healius Ltd (ASX:HLS) reported a revenue growth of 3.8% to $688.1 million, despite lower episode volumes and flat MBs volumes.
- Pathology revenue increased by 3.5%, with Agilex delivering a strong revenue growth of 16% to $21.8 million.
- Underlying EBITDA increased by 13.1% to $122.2 million, reflecting improved operating leverage and benefits from cost reduction initiatives.
- The company ended the period with a net cash position of $11.6 million, indicating strong cash management.
- Healius Ltd has successfully deployed AI co-workers, Reva AI and Julie AI, to improve cash flows and workforce planning, marking progress in their AI journey.
- The Fair Work Commission decision on gender-based undervaluation is expected to have a $1.8 million impact in 4Q26, with further financial implications yet to be determined.
- Operationally, GP attendances were down 1.5%, and MBs volumes remained flat, indicating challenges in volume growth.
- The company faces ongoing restructuring costs and challenges in reducing labor costs, which remain a key focus area.
- Interest costs, primarily from finance costs on properties, remain a concern, although they are down versus the prior period.
- The impact of the Fair Work Commission decision and potential changes in Medicare Benefits Schedule could pose financial challenges moving forward.
Thank you for standing by and welcome to the Helio 1H26 results. All participants are in listen-only mode. There will be a presentation followed by a question-and-answer session. If you wish to ask a question, you will need to press the star key followed by the number 1 on your telephone keypad. I would now like to hand the conference over to Mr. Paul Anderson, MD and CEO. Please go ahead.
Good morning and thank you everyone for joining us today. Alongside me is our Chief Financial Officer, Andrew Thompson, who will present the financial results in detail later on in the presentation.
Today we're presenting our results for the first half of FY26.
We have delivered revenue growth on lower than normal episode volumes in an environment of flat MBs volumes.
Costs out benefits and in particular labor are now being realized and we're making tangible progress against our strategy.
We're very much focused on improving customer service for patients
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
